Company intelligence / Profile preview

Paracrine, Inc.

San Diego, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 3

Overview

Currently conducting FDA-approved Phase III ASCEND trial for diabetic foot ulcers. Prior independent feasibility studies demonstrated an 88% wound closure rate, nearly four times the standard of care from a single treatment, with rapid and durable healing and no recurrences reported up to 18 months follow-up.

Therapeutic areas: EndocrinologyRheumatologyCardiovascularDermatology
Modalities: Cell therapyAdipose-Derived Regenerative Cells (ADRCs)
Industry: Biotech

Drug pipeline

1 asset

Celution-processed ADRCs

Phase 3

Indications: Diffuse cutaneous scleroderma, Hand dysfunction, Diabetic foot ulcers

Partnerships

GE HealthcareAstellasOlympus MedicalBARDAMedtronicKensey Nash

Beyond the preview

Go deeper on Paracrine, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paracrine, Inc..

Explore the full profile